

AMENDMENTS TO THE SPECIFICATION

Page 1, just under the title, please insert the following new paragraph:

This application is a 371 of PCT/JP04/15005 10/05/2004.

Page 1, delete the third full paragraph and insert the following new paragraph:

β1-adrenoceptors are located predominantly on the heart, and stimulation of β1-adrenoceptors invokes increases in heart rate and potentiation of cardiac contractility. β2-adrenoceptors are found abundantly on smooth muscles of blood vessels, bronchi and the uterus, and stimulation of β2-adrenoceptors leads to vasodilation, bronchodilation and inhibition of uterine contraction. A variety of β1- and β2-adrenoceptor stimulants have been developed so far and utilized as cardiotonics, bronchodilators, prophylactic agents for threatened[[,]] abortion or premature labor and the like.

Delete the full paragraph bridging page 1 and 2, insert the following new paragraph:

It has been reported that β3-adrenoceptors are located in adipocytes, the brain, gall bladder, prostate, urinary bladder, intestinal tract and the like (see nonpatent literatures 1, 2, 3 and 4), and stimulation of β3-adrenoceptors promotes lipolysis, increased thermogenesis, hypoglycemic activities; hypolipidemic activities such as triglyceride lowering activities, hypocholesterolemic activities, HDL-cholesterol increasing activities and the like; antidepressive activities; urinary bladder relaxing activities; suppression of intestinal motility and the like (see nonpatent literatures 2, 5, 6 and 7). Accordingly, β3-adrenoceptor agonists are expected to be useful for treating or preventing obesity, diabetes mellitus, hyperlipidemia, depression,

urinary dysfunctions, diseases caused by biliary tract hypermotility, or diseases caused by intestinal hypermotility.

Page 2, delete the first full paragraph and insert the following new paragraph:

Recent studies on β 3-adrenoceptor agonists have been focused mainly on developing an anti-obesity or anti-diabetic agent. However, many of such β 3-adrenoceptor agonists have been accompanied with adverse reactions such as increased heart rate, muscle tremors, hypokalemia and the like, which ~~resulted from stimulation~~ of β 1- and/or β 2-adrenoceptors. It has also been reported that activities of β 3-adrenoceptor agonists differ markedly among species, and some compounds exhibit less potent stimulating activities on human β 3-adrenoceptors than on those of a rodent such as rat β 3-adrenoceptors (see nonpatent literature 8). Accordingly, it has been greatly desired to develop for novel agents exhibiting potent stimulating activities on human β 3-adrenoceptors with less adverse reactions caused by stimulation of β 1- and β 2-drenoceptors.

Page 58, delete the second full paragraph and insert the following new paragraph:

The compounds of the present invention suppress intestinal ~~motility~~metilities, and are accordingly useful as a therapeutic or prophylactic agent for diseases caused by intestinal hypermotility such as esophageal achalasia, gastritis, cholecystitis, pancreatitis, peritonitis, infectious enteritis, ulcerative colitis, Crohn's disease, irritable bowel syndrome, colon diverticulitis, simple diarrhea and the like.